1-benzenesulfonyl-3-(N,N-dimethylaminomethyl)indole | 58550-82-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-benzenesulfonyl-3-(N,N-dimethylaminomethyl)indole
• 英文别名: 1-benzenesulfonylgramine；1-benzenesulfonyl-3-dimethylaminomethyl-indole；1-Benzolsulfonylgramin；N-benzenesulfonylgramine antagonist, 8；1-[1-(benzenesulfonyl)indol-3-yl]-N,N-dimethylmethanamine
• CAS: 58550-82-6
• 化学式: C₁₇H₁₈N₂O₂S
• 分子量: 314.408
• InChiKey: MHFSWNYVTLJUEH-UHFFFAOYSA-N

物化性质

• 熔点：
  77-79 °C
• 沸点：
  476.9±37.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  50.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(苯基磺酰基)-3-甲基吲哚 生成 1-benzenesulfonyl-3-(N,N-dimethylaminomethyl)indole
  参考文献：
  名称：

  HINO T.; NAKAMURA T.; NAKAGAWA M., CHEM. AND PHARM. BULL. , 1975, 23, NO 11, 2990-2997

  摘要：

  DOI：

文献信息

• A Practical Synthesis of Indole-Based Heterocycles Using an Amidoaluminum-Mediated Strategy
  作者：M. Hossain、Robert Todd

  DOI：10.1055/s-0028-1088071

  日期：2009.6

  A large number of biologically active compounds consist of an indole scaffolding. Because of this, chemists are continually searching for more efficient means through which to successfully synthesize the required alkaloids. In our recent effort to synthesize indole-based p38 inhibitors and gramines, we found that a series of indole-based indole-3-carboxamides could be efficiently synthesized from various indole-3-carboxylates using an amidoaluminum-mediated strategy. The treatment of ethyl indole-3-carboxylates bearing a range of substitution patterns on the indole ring with various amidoaluminum complexes, led to the corresponding 1H-indole-3-carboxamides in yields up to 75%. Reduction by diisobutylaluminum hydride afforded the corresponding gramines in 63-85% yield. This is the first reported example of amidoaluminum complexes of type Al2(CH3)4(NR2)2 promoting facile amidation of relatively inert indole esters. This particularly promising approach has resulted in the first strategy for generating medicinally important alkaloids of this type.

  大量生物活性化合物含有吲哚骨架。因此，化学家们不断寻找更有效的方法来成功合成所需的生物碱。在我们最近努力合成基于吲哚的p38抑制剂和尼亚辛时，我们发现一系列基于吲哚的吲哚-3-羧酰胺可以通过酰胺铝介导的策略从各种吲哚-3-羧酸盐高效合成。用各种酰胺铝复合物处理带有不同取代模式的吲哚环的乙基吲哚-3-羧酸盐，得到了相应的1H-吲哚-3-羧酰胺，收率高达75%。通过二异丁基铝氢还原得到了相应的尼亚辛，收率为63-85%。这是首次报道的类型为Al2(CH3)4(NR2)2的酰胺铝复合物促进相对惰性的吲哚酯的易于酰胺化的例子。这种特别有希望的方法已经产生了一种生成这种类型的具有药用重要性的生物碱的首创策略。
• LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF
  申请人：Alla Chem, LLC.

  公开号：EP2184064A2

  公开（公告）日：2010-05-12

  The invention relates to novel ligands of 5-HT6 receptor, to a pharmaceutical composition containing said novel ligands of 5-HT6 receptor as active component and to novel medicaments used for humans and warm-blooded animals for treating diseases and conditions of central nervous system, in pathogenesis of which neuromediator systems induced by 5-HT6 receptors are playing an essential role. Azaheterocyclic compounds of the general formula 1 or racemates, or optical or geometrical isomers, or pharmaceutically acceptable salts and/or hydrates thereof are used as 5-HT6 ligands. Wherein R2 and R3 independently of each other represent an amino group substituent selected from hydrogen; substituted carbonyl; substituted aminocarbonyl; substituted aminothiocarbonyl; substituted sulphonyl; C1-C5-alkyl optionally substituted by: C6-C10-arylaminocarbonyl, heterocyclyl, C6-C10-arylaminocarbonyl, C6-C10-arylaminothiocarbonyl, C5-C10-azaheteroaryl, optionally substituted carboxyl, nitryl group, optionally substituted aryl; R1k represents from 1 to 3 substituents of cyclic system, independent of each other and selected from hydrogen, optionally substituted C1-C5-alkyl, C1-C5-alkoxy, C1-C5-alkenyl, C1-C5-alkynyl, halogen, trifluoromethyl, CN-group, carboxyl, optionally substituted aryl, optionally substituted heterocyclyl, substituted sulfonyl, optionally substituted carboxyl; the solid line accompanied by the dotted line (---) represents a single or a double bond; n=1,2 or 3.

  本发明涉及 5-HT6 受体的新型配体、含有所述 5-HT6 受体新型配体作为活性成分的药物组合物以及用于人类和温血动物治疗中枢神经系统疾病和病症的新型药物，在中枢神经系统疾病和病症的发病机制中，5-HT6 受体诱导的神经介导系统发挥着重要作用。 通式 1 的杂杂环化合物或外消旋体，或光学或几何异构体，或其药学上可接受的盐和/或水合物可用作 5-HT6 配体。 其中，R2 和 R3 相互独立地代表一个氨基取代基，该取代基选自氢；取代的羰基；取代的氨基羰基；取代的氨基硫代羰基；取代的磺酰基；任选被以下取代的 C1-C5- 烷基：C6-C10-芳基氨基羰基：C6-C10-芳基氨基羰基、杂环烷基、C6-C10-芳基氨基羰基、C6-C10-芳基氨基硫代羰基、C5-C10-氮杂环芳基、任选取代的羧基、硝基、任选取代的芳基；R1k 代表 1 至 3 个相互独立的环状体系取代基，选自氢、任选取代的 C1-C5- 烷基、C1-C5-烷氧基、C1-C5-烯基、C1-C5-炔基、卤素、三氟甲基、CN 基、羧基、任选取代的芳基、任选取代的杂环基、取代的磺酰基、任选取代的羧基；伴随虚线 (---) 的实线代表单键或双键；n=1、2 或 3。
• N1-Benzenesulfonylgramine and N1-benzenesulfonylskatole: novel 5-HT6 receptor ligand templates
  作者：Manik R. Pullagurla、Małgorzata Dukat、Vincent Setola、Bryan Roth、Richard A. Glennon

  DOI：10.1016/s0960-894x(03)00612-7

  日期：2003.10

  1-Benzenesulfonyl-5-methoxy-N,N-dimethyltryptamine (3; K-i=2.3 nM) is a 5-HT6 receptor antagonist: removal of the 5-methoxy group (i.e., 6; K-i = 4.1 nM) has little impact on receptor affinity. In the present study, it is shown that the aminomethyl portion of 6 can be shortened to gramine analogue 10a (K-i = 3.1 nM) a related skatole derivative 11b (K-i = 12 nM) also binds with high affinity indicating that the aminoethyl portion of the tryptamines is not required Cor binding. Compounds 10a and 11b represent members of novel classes of 5-HT6 antagonists. (C) 2003 Elsevier Ltd. All rights reserved.
• [EN] LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF<br/>[FR] LIGAND DES RÉCEPTEURS 5-HT6, COMPOSITION PHARMACEUTIQUE ET PROCÉDÉ DE FABRICATION ET D'UTILISATION
  申请人：ALLA CHEM LLC

  公开号：WO2008060190A2

  公开（公告）日：2008-05-22

  [EN] The invention relates to novel ligands of 5-HT₆ receptor, to a pharmaceutical composition containing said novel ligands of 5-HT₆ receptor in the form of an active component and to novel medicinal preparations which are used for human beings and homoiotherms for treating diseases and states of the central nervous system, in the pathogenesis of which neurotransmitter systems modulated by 5-HT₆ receptors play a substantial role. Asaheterocyclic compound of general formula 1 or the racemates thereof or the optical or geometrical isomers thereof, or the pharmaceutically acceptable salts and/or hydrates thereof are used in the form of 5-HT₆ ligands. Wherein R2 and R3 independently from each other represent an aminogroup substituent selected from hydrogen, substituted carbonyl, substituted aminocarbonyl, substituted aminothiocarbonyl, substituted sulphonyl, C₁-C₅-alkyl optionally substituted by C₆-C₁₀-arylaminocarbonyl, optionally substituted by heterocyclyl, by C₆-C₁₀- arylaminocarbonyl, by C₆-C₁₀ -arylaminothiocarbonyl, by C₅-C₁₀-azaheteroaryl, optionally substituted by carboxyl, by a nitryl group and optionally substituted aryl; R¹ _k
  [FR] La présente invention concerne de nouveaux ligands du récepteur de sérotonine 5-HT₆, une composition pharmaceutique contenant en tant que principe actif de nouveaux ligands du récepteur de sérotonine 5-HT_6, de nouvelles formulations destinées aux humains ou aux animaux à sang chaud, qui s'utilisent dans le traitement de maladies et d'états du système nerveux central dans la pathogénèse desquels un rôle important est joué par des systèmes neuromédiateurs, modulés par les récepteurs 5-HT_6.On propose d'utiliser en tant que récepteur 5-HT₆des compositions aza-hétérocyliques correspondant à la formule générale (1) ou leurs racémates ou leurs isomères optiques ou leurs isomères géométriques ou leurs sels et/ou hydrates pharmaceutiquement acceptables (formule 1), dans laquelle R2 et R3 sont indépendamment un substituant de groupe amino sélectionné parmi hydrogène; carbonyle substitué; aminocarbonyle substitué; aminothiocarbonyle substitué; sulfonyle substitué; alkyle C₁-C₅éventuellement substitué par aryle C₆-C₁₀, éventuellement substitué par hétérocycle, par arylaminocarbonyle C₆-C₁₀, par arylaminothiocarbonyle C₆-C₁₀, par azahétéroaryle C₆-C₁₀, éventuellement substitué par carboxyle, par groupe nitryle, par aryle éventuellement substitué; et R¹ _k
• HINO T.; NAKAMURA T.; NAKAGAWA M., CHEM. AND PHARM. BULL. <CPBT-AL>, 1975, 23, NO 11, 2990-2997
  作者：HINO T.、 NAKAMURA T.、 NAKAGAWA M.

  DOI：——

  日期：——